Statin and aspirin for prevention of hepatocellular carcinoma: What are the levels of evidence?

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 1, 2014, Pages 9-11

  Carrat, Fabrice ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CARCINOMA, HEPATOCELLULAR; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER NEOPLASMS;

EID: 84893957135     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2013.09.007     Document Type: Short Survey

References (16)

1. Tsan Y.T., Lee C.H., Wang J.D., Chen P.C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012, 30(6):623-630.
2. Singh S., Singh P.P., Singh A.G., Murad M.H., Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013, 144(2):323-332.
3. Sahasrabuddhe V.V., Gunja M.Z., Graubard B.I., et al. Nonsteroidal anti-inflammatory drug use chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst 2012, 104(23):1808-1814.
4. Levesque L.E., Hanley J.A., Kezouh A., Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010, 340:b5087.
5. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., White C.M. Statins and cancer risk: a meta-analysis. JAMA 2006, 295(1):74-80.
6. Cholesterol Treatment Trialists, Emberson J.R., Kearney P.M., et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012, 7(1):e29849.
7. Sandler R.S., Halabi S., Baron J.A., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348(10):883-890.
8. Burn J., Gerdes A.M., Macrae F., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, 378(9809):2081-2087.
9. Cook N.R., Lee I.M., Gaziano J.M., et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005, 294(1):47-55.
10. Cook N.R., Lee I.M., Zhang S.M., Moorthy M.V., Buring J.E. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013, 159(2):77-85.
11. Sturmer T., Glynn R.J., Lee I.M., Manson J.E., Buring J.E., Hennekens C.H. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 1998, 128(9):713-720.
12. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377(9759):31-41.
13. Rothwell P.M., Price J.F., Fowkes F.G., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379(9826):1602-1612.
14. Rothwell P.M., Wilson M., Price J.F., Belch J.F., Meade T.W., Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379(9826):1591-1601.
15. Venook A.P., Papandreou C., Furuse J., de Guevara L.L. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 4(15Suppl):5-13.
16. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61(10):1942-1956.